(MENAFN- PR Newswire) Considering the expected launch of new upcoming therapies and greater integration of early patient screening, it can be safely assumed that the MI market will undergo a paradigm shift in the present decade holding new prospects and opportunities for those planning to carve out their niche during the forecast period [2022–2032]
LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's mi market insights
report includes a comprehensive understanding of current treatment practices, MI emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the MI Market Report
As per DelveInsight analysis, the MI
market size in the 7MM was approximately USD 21 billion in 2021 According to the assessment done by DelveInsight, the estimated total MI diagnosed prevalent cases in the 7MM was approximately 15 million in 2021 Leading MI
companies such as AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast , and others are developing novel MI drugs that can be available in the MI market in the coming years The promising MI
therapies in the pipeline include FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC , and others In November 2022, Amgen presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine As per the Q32022 investor presentation of AstraZeneca data, readouts from the Phase III (DAPA-MI) trial of FARXIGA/FORXIGA is anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023 In June 2021, Idorsia announced the initiation of the Phase III registration study 'SOS-AMI' to evaluate the efficacy and safety of self-administered SC selatogrel in suspected AMI In September 2020, the FDA granted Fast Track designation for the development of JARDIANCE to prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute MI In July 2020, AstraZeneca was granted Fast Track designatio n in the US for the development of FARXIGA to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an AMI or heart attack
Discover which therapies are expected to grab the major MI
market share @ mi market report .
MI Overview
MI is pathologically defined as myocardial cell death caused by prolonged ischemia. The first ultrastructural changes are diminished cellular glycogen, relaxed myofibrils, and sarcolemmal disruption, which can be seen as early as 10-15 minutes after the onset of ischemia. Symptoms of MI include chest pain, which may initially manifest as a sensation of tightness or pressure. The pain usually radiates to the left arm, but it can also radiate to the lower jaw, neck, right arm, back, and upper abdomen. Sweating, nausea, vomiting, and fainting may accompany chest pain.
The typical clinical features, ECG findings, and elevation of cardiac biomarkers are used for MI diagnosis. Cardiovascular catheterization is required for definitive diagnosis and serves diagnostic and therapeutic purposes. All patients suspected of having ACS should be considered for emergency revascularization; other MI treatment options include anticoagulation, antiplatelet therapy, statin therapy, and other adjunctive measures.
MI Epidemiology Segmentation
DelveInsight estimates that there were approximately 15 million diagnosed prevalent cases of mi
in the 7MM in 2021.
Among EU4 countries, Germany had the highest number of diagnosed prevalent cases of MI, while Spain had the lowest prevalent population among the 7MM.
The mi market report
proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Diagnosed Prevalent Cases Gender-specific Prevalence Type-specific Prevalence
Download the report to understand which factors are driving MI
epidemiology trends @ mi epidemiological insights .
MI Treatment Market
The goals of initial MI
treatment are to relieve pain, immediately identify ST changes via 12-lead EKG, initiate reperfusion (if the patient is a candidate), and assess and treat hemodynamic abnormalities. Oxygen, nitroglycerin, and morphine sulfate are the most effective pain relievers. Reperfusion therapy is indicated for patients with ST-segment elevation or a new LBBB with symptoms lasting 12 hours or less. MI treatment may be divided into two paths depending on whether the patient has a STEMI or an NSTEMI. The pharmacologic MI treatment is further subdivided into several groups of medications that improve survival, reduce recurrent ischemic events, and provide symptomatic relief. Following the primary MI treatment, a multimodal regimen of therapies is used. To classify the disease, rapid diagnostic tests and serial biomarker analysis are used to begin MI treatment.
The current MI market has been segmented into different commonly used therapeutic classes based on the prevailing MI treatment pattern across the 7MM, which exhibits minor variations in the overall prescription pattern. The major classes covered in the forecast model are antiplatelet agents, anticoagulants, vasodilators, beta-blockers, lipid-lowering drugs, Angiotensin-converting enzyme (ACE) inhibitors, ARBs (Angiotensin-II receptor Blockers), and calcium channel blockers .
In recent years, it has been demonstrated that pre-hospital thrombolysis has a role in the management of patients seen early after symptom onset in comparison/association with patients who had primary coronary intervention or elective primary coronary intervention. This is an important issue that is still being researched to prevent cardiac arrest, large scares, and again limit the transition to heart failure and improve the survival rate after AMI.
To know more about MI treatment guidelines, visit @ mi management .
MI Pipeline Therapies and Key Companies
FARXIGA/FORXIGA (dapagliflozin): AstraZeneca JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company Pelacarsen (TQJ230): Novartis Olpasiran: Amgen Selatogrel: Idorsia Pharmaceuticals FDY-5301: Faraday Pharmaceuticals CSL112: CSL Behring IMT-358: Immediate Therapeutics CL2020: Mitsubishi Chemical Group MEDI6570: AstraZeneca KAND567: Kancera Asundexian: Bayer Dutogliptin: Recardio MPC-25-IC: Mesoblast
Learn more about the FDA-approved drugs for MI @ drugs for mi treatment .
mi market dynamics
The dynamics of MI market is anticipated to change in the coming years. The growing emphasis on secondary preventive measures to avoid recurrent/new events, lifestyle changes , and the growing number of smokers and cases of obesity, diabetes, hypertension , and others, are expected to fuel MI market growth. Moreover, heart attacks and strokes are major cost drivers in the 7MM healthcare system. The volume of the MI
market is enormous. The patient is receiving multiple therapies at the same time. The smallest portion of the patient share can provide pharmaceutical companies with options worth millions of dollars in the MI market.
However, several factors are likely to affect the growth of the MI market.
Women appear to be underdiagnosed with MI , despite being at higher risk because medical training for healthcare professionals and public information has emphasized the identification of symptoms that typically affect men. This highlights the importance of gender differences in developing strategies for early MI
detection and tailored secondary prevention after MI, which should result in a higher rate of MI
detection in women.
Moreover, off-label therapies and generics account for the majority of the current MI
market because they are less expensive and more easily accessible to patients, thus, causing a dip in the MI market growth. Hence, all these factors mentioned above will hamper the MI market growth in the future.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan |
| Base Year | 2019 |
| MI Market CAGR | 1.61
% |
| MI Market Size in 2021 | USD 21 Billion |
| Key MI Companies | AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others |
| Key Pipeline MI Therapies | FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Pelacarsen (TQJ230), Olpasiran, Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others |
Scope of the MI
Market Report
Therapeutic Assessment: MI
current marketed and emerging therapies MI
Market Dynamics:
MI
market drivers and barriers
Competitive Intelligence Analysis:
SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, MI Market Access and Reimbursement
Discover more about MI drugs
in development @ mi clinical trials .
Table of Contents
| 1. | MI Market Key Insights |
| 2. | MI Market Report Introduction |
| 3. | MI Executive Summary |
| 4. | MI Key Events |
| 5. | Epidemiology and Market Methodology |
| 6. | MI Market Overview at a Glance |
| 7. | MI Disease Background and Overview |
| 8. | MI Treatment and Management |
| 9. | Guidelines and Recommendations for MI |
| 10. | MI Epidemiology and Patient Population |
| 10.1 | Key Findings |
| 10.2 | Assumptions and Rationale |
| 10.3 | Total Diagnosed Prevalent Patient Population of MI in the 7MM |
| 10.4 | United States |
| 10.5 | EU4 and the UK |
| 10.6 | Japan |
| 11. | Patient Journey |
| 12. | MI Marketed Drugs |
| 13. | MI Emerging Drugs |
| 14. | Seven Major MI Market Analysis |
| 14.1 | Key Findings |
| 14.2 | Total Market Size of MI in the 7MM |
| 14.3 | Market Outlook |
| 14.4 | Attribute Analysis |
| 14.5 | Key Market Forecast Assumptions |
| 14.6 | United States Market Size |
| 14.7 | EU4 and the UK Market Size |
| 14.8 | Japan Market Size |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | KOL Views |
| 18. | Market Access and Reimbursement |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Related Reports
mi pipeline
MI Pipeline Insight – 2023
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
MI
companies, including CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, among others.
mi epidemiology forecast
MI Epidemiology Forecast – 2032
report delivers an in-depth understanding of the disease, historical and forecasted MI
epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
myocarditis pipeline
Myocarditis Pipeline Insight – 2023
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
myocarditis companies, including Cantargia AB, Cardiol Therapeutics, Apitope, among others.
dilated cardiomyopathy pipeline
Dilated Cardiomyopathy Pipeline Insight – 2023
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dilated cardiomyopathy companies, including Longeveron, Bristol Myers Squibb, Berlin Cures, Tenaya Therapeutics, Cardior Pharmaceuticals, among others.
cardiac biomarkers testing market
Cardiac Biomarkers Testing
Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cardiac biomarkers testing companies, including Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, among others.
dilated cardiomyopathy epidemiology
Dilated Cardiomyopathy Epidemiology Forecast – 2032
report delivers an in-depth understanding of the disease, historical, and forecasted dilated cardiomyopathy epidemiology in the 7MM.
Other Trending Reports
tay-sachs disease or gm2 gangliosidosis market |
onycholysis market |
diagnostic imaging equipment market |
chemotherapy-induced peripheral neuropathy market |
global electrophysiology devices market |
anaphylaxis market |
atherectomy devices market |
helicobacter pylori infections market |
ophthalmic imaging equipment market |
androgenetic alopecia market |
allergic rhinitis market |
chronic inflammatory demyelinating polyneuropathy market |
chronic inflammatory demyelinating polyneuropathy market |
colorectal cancer crc market |
opioid induced constipation market |
vertigo market |
bone anchored hearing systems market | wound closure devices market |
hip replacement devices market |
hemodynamic monitoring systems market
| egfr non-small cell lung cancer market |
helicobacter pylori infection market |
hyperkalemia market |
polycythemia market
neurostimulation devices market |
carpal tunnel syndrome market | ventilator market |
cerebral aneurysm market |
alpha antitrypsin market |
binge eating disorder market | bunion market |
concussions market size |
exocrine pancreatic insufficiency market |
healthcare due diligence services |
minimal residual disease market | hypertrophic scar market | lung fibrosis market | anterior uveitis market | 22q11.2 deletion syndrome market | x-linked retinitis pigmentosa (xlrp) market | acute radiation syndrome market | alpha-1 protease inhibitor deficiency market | androgenetic alopecia market | hyperlipidemia market | cardiotoxicity market | hypertrophic cardiomyopathy market | fatty acid oxidation disorders (faods) market | androgen insensitivity syndrome market | emphysema market | canaloplasty market | dravet syndrome market | celiac disease market | chlamydia infections market | syphilis market | renal tubular acidosis market | palmoplantar pustulosis (ppp) market | aplastic anemia market | bacterial pneumonia market | b cell chronic lymphocytic leukemia market | b cell lymphomas market | behcets disease market neoantigen-based personalized cancer therapeutic vaccines competitive landscape and market forecast-by 2035 | glioblastoma market
Related Healthcare Blogs
upcoming cardiovascular diseases drugs
key companies in the cardiology segment
heart failure market
Related Healthcare Services
healthcare consulting
healthcare competitive intelligence services
healthcare asset prioritization services
About
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform
PharmDelve.
Connect with us on: linkedin | facebook | twitter .
Additionally, get in touch with our business executive to explore @
healthcare due diligence services .
Logo -
Contact Us:
Shruti Thakur
[email protected]
+1(919)321-6187
SOURCE DelveInsight Business Research, LLP